Hexarelin

Overview

Hexarelin (examorelin, EP 23905) is a synthetic hexapeptide growth hormone secretagogue developed in the early 1990s by Romano Deghenghi and colleagues at Europeptides [3]. Its amino acid sequence is His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH₂, with a molecular weight of approximately 887 Da. Hexarelin was designed as a structural modification of GHRP-6, incorporating a D-2-methyltryptophan substitution that confers enhanced metabolic stability and increased GH-releasing potency [1][3].

Among the growth hormone-releasing peptides (GHRPs), hexarelin produces the most potent acute GH release in humans. In the landmark 1994 clinical study by Ghigo et al., intravenous hexarelin at 1-2 μg/kg elicited robust GH peaks in healthy volunteers via multiple routes of administration including intravenous, subcutaneous, intranasal, and oral [1]. However, hexarelin also elevates cortisol and prolactin at effective GH-releasing doses, distinguishing it from more selective secretagogues such as ipamorelin [4][20].

The most pharmacologically distinctive aspect of hexarelin is its demonstration of direct cardioprotective effects independent of GH release, mediated through binding to the CD36 scavenger receptor on cardiomyocytes [11]. This dual receptor activity (GHS-R1a and CD36) led to Phase II clinical investigation for both GH deficiency diagnosis and cardiac indications, though development was ultimately discontinued [19][24].

Molecular Weight

887.04 Da

Sequence

His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH₂

Half-life

~70 minutes (IV)

Routes Studied

Intravenous, subcutaneous, intranasal, oral

FDA Status

Not approved (Phase II discontinued)

WADA Status

Prohibited under S2 (peptide hormones, growth factors)

Key Receptors

GHS-R1a (ghrelin receptor), CD36 (cardiac)

Mechanism of Action

Hexarelin exerts its biological effects through two distinct receptor systems, making it unique among growth hormone secretagogues.

GHS-R1a (Ghrelin Receptor) Activation

Hexarelin binds to the growth hormone secretagogue receptor type 1a (GHS-R1a), a G-protein coupled receptor expressed primarily on somatotroph cells of the anterior pituitary and in multiple brain regions [3][24]. Receptor activation triggers phospholipase C signaling, inositol 1,4,5-trisphosphate production, and subsequent increases in intracellular calcium, leading to GH exocytosis [3].

The GH-releasing effect of hexarelin is complementary to and synergistic with growth hormone-releasing hormone (GHRH). While GHRH acts through the GHRH receptor via a cAMP-dependent pathway, hexarelin activates the GHS-R1a through a phospholipase C-dependent mechanism. Combined administration of low-dose hexarelin with GHRH produces synergistic GH release far exceeding the response to either agent alone [1][9].

Hexarelin also stimulates GH release at the hypothalamic level by promoting GHRH neuron activity and by antagonizing somatostatin tone, providing a dual site of action (hypothalamic and pituitary) [3][24].

CD36 Receptor Binding (Cardiac)

The identification of CD36 as a specific hexarelin receptor in cardiac tissue represents a landmark finding in GHRP pharmacology. Papotti et al. (2000) first demonstrated that GHS binding sites were present at highest density in human myocardium, exceeding binding in all other peripheral tissues examined including adrenal, gonads, arteries, and liver [10].

Bodart et al. (2002) subsequently identified CD36, an 88 kDa multifunctional glycoprotein expressed on cardiomyocytes and microvascular endothelial cells, as the specific cardiac receptor responsible for the cardiovascular effects of hexarelin [11]. Using photoaffinity cross-linking with radiolabeled hexarelin derivatives, they mapped the binding site to the CD36-(Asn132-Glu177) sequence, with Met169 as the primary contact residue [11].

Critically, the cardioprotective effects of hexarelin were absent in hearts from CD36-null mice and spontaneously hypertensive rats genetically deficient in CD36, confirming the receptor dependence of these effects [11].

Neuroendocrine Effects Beyond GH

Unlike ipamorelin, hexarelin activates multiple neuroendocrine pathways at GH-releasing doses:

• ACTH and cortisol: Dose-dependent stimulation, with approximately 40% maximal cortisol increase at 0.5 μg/kg IV [4]
• Prolactin: Approximately 80% increase from baseline at standard doses [4]
• Aldosterone: Modest increases observed at higher doses [4]

These off-target endocrine effects are dose-dependent, with low doses (0.25 μg/kg) producing minimal cortisol and prolactin changes while retaining significant GH-releasing activity [4][9].

Comparison with Other Growth Hormone Secretagogues

| Compound | GH Potency | Cortisol Effect | Prolactin Effect | ACTH Effect | Desensitization | |---|---|---|---|---|---| | Hexarelin | Highest [1] | Significant [4] | Significant [4] | Significant [4] | Pronounced [15] | | GHRP-6 | High [20] | Moderate [20] | Moderate [20] | Moderate [20] | Moderate | | GHRP-2 | High [20] | Moderate [20] | Moderate [20] | Moderate [20] | Moderate | | Ipamorelin | Moderate [20] | Minimal [20] | Minimal [20] | Minimal [20] | Mild |

Researched Applications

All applications listed below are investigational. Hexarelin is not approved for clinical use in any indication.

Diagnosis of GH Deficiency

Hexarelin alone and in combination with GHRH has been investigated as a GH stimulation test for diagnosing adult GH deficiency (GHD). Aimaretti et al. (1999) demonstrated that the combined low-dose hexarelin (0.25 μg/kg) plus GHRH test was as sensitive as the insulin tolerance test (ITT, the gold standard) for diagnosing adult GHD [9]. This combination offered the advantage of avoiding insulin-induced hypoglycemia while maintaining diagnostic accuracy.

In GHD patients, the mean GH peak after GHRH plus hexarelin was comparable to that after GHRH plus arginine, and both exceeded the response to ITT alone [9]. The test distinguished between GHD patients and normal subjects with high sensitivity and specificity when appropriate cutoff values were applied.

Cardiac Function and Cardioprotection

Hexarelin's cardiac effects represent its most distinctive therapeutic potential and have been investigated across multiple clinical settings:

Hypopituitary patients (Bisi et al. 1999): In seven adult males with severe GH deficiency, intravenous hexarelin (2 μg/kg) increased LVEF from 50 ± 1% to 57 ± 2% (P <0.05), despite negligible GH release (peak 1.9 ± 0.9 μg/L versus 45.7 ± 3.6 μg/L in controls) [6]. This was among the first clinical demonstrations that hexarelin's cardiac effects occur independently of GH release.

Healthy volunteers (Broglio et al. 1999): In normal male subjects, hexarelin increased LVEF from 64.0 ± 1.5% to 70.7 ± 3.0% (P <0.03), with the effect appearing at 15 minutes, peaking at 30 minutes, and lasting up to 60 minutes [7]. Notably, recombinant human GH administration did not affect LVEF in the same volunteers, supporting a GH-independent mechanism.

Coronary bypass surgery (Imazio et al. 2002): In 24 male patients with coronary artery disease undergoing bypass surgery, intravenous hexarelin induced a prompt increase in LVEF (P <0.001), cardiac index (P <0.001), and cardiac output (P <0.001) lasting up to 90 minutes, without significant changes in systemic vascular resistance [12]. This cardiotropic effect was not shared by GHRH or recombinant GH, confirming activation of specific cardiovascular GHS receptors.

Severe cardiomyopathy (Broglio et al. 2002): In patients with severe left ventricular dysfunction due to dilated and ischemic cardiomyopathy, hexarelin demonstrated GH-independent positive inotropic effects, with similar LVEF improvements observed in patients with and without residual GH secretory capacity [13].

Ischemia-Reperfusion Protection

GH-independent cardioprotection in rats (Locatelli et al. 1999): Hexarelin protected against ischemia-reperfusion injury even in hypophysectomized rats lacking the capacity for GH release, and prevented endothelial vasodilator dysfunction in aortic rings of hypophysectomized animals [8]. This study provided definitive evidence that hexarelin's cardiac benefits are GH-independent.

Acute myocardial infarction (McDonald et al. 2018): In mice with MI induced by coronary artery ligation, hexarelin (0.3 mg/kg/day for 21 days) significantly improved LV function after 14 days and reduced LV mass, interstitial collagen, and collagen concentration at 21 days [17].

Anti-Fibrotic Effects

Hypertensive cardiac fibrosis (Zhang et al. 2012): Five weeks of hexarelin treatment in spontaneously hypertensive rats significantly reduced cardiac fibrosis by decreasing interstitial and perivascular collagen deposition, reducing collagen I and III expression, increasing MMP-2 and MMP-9 activity, and attenuating LV hypertrophy and diastolic dysfunction [18]. These effects were abolished by a selective GHS-R antagonist, confirming receptor-mediated action.

Anti-Apoptotic Effects

Hexarelin inhibits cardiomyocyte apoptosis through multiple pathways. Sun et al. (2003) demonstrated that hexarelin protects rat cardiomyocytes from angiotensin II-induced apoptosis by inhibiting caspase-3 activity, decreasing pro-apoptotic Bax expression, and increasing anti-apoptotic Bcl-2 expression [23].

Metabolic Effects

Berlanga-Acosta et al. (2017) showed that hexarelin (200 μg/kg twice daily for 12 days) improved lipid metabolic aberrations in insulin-resistant MKR mice, producing a 3.3% increase in lean mass and decreased fat mass [22]. In elderly humans, peak GH response to hexarelin correlated negatively with body fat mass, BMI, and percentage body fat, with total fat mass serving as a predictor of GH response magnitude [15].

Pediatric Growth

Laron et al. (1995) administered intranasal hexarelin (60 μg/kg three times daily) to 8 prepubertal short children for up to 8 months. Treatment raised IGF-I levels from 10.4 ± 3.9 to 14.1 ± 4.6 nmol/L and increased mean growth velocity from 5.3 ± 0.8 to 8.3 ± 1.7 cm/year [16]. Partial GH desensitization occurred but did not abolish the growth-promoting effect.

Clinical Evidence Summary

The clinical evidence for hexarelin spans GH physiology, diagnostic endocrinology, and cardiovascular medicine:

GH Release and Dose-Response:

• Ghigo et al. (1994): First human study demonstrating hexarelin's GH-releasing activity across IV, SC, intranasal, and oral routes in 12 healthy volunteers. IV dose of 1-2 μg/kg produced robust GH peaks [1].
• Imbimbo et al. (1994): Dose-response study establishing ED50 of 0.48 ± 0.02 μg/kg for GH release, with GH plateau at approximately 140 mU/L corresponding to 1.0 μg/kg [2].
• Arvat et al. (1997): Characterized dose-dependent cortisol (~40% increase at 0.5 μg/kg) and prolactin (~80% increase) responses, establishing the hormonal profile across doses [4].

Age-Related Variations:

• Arvat et al. (1997): Demonstrated that hexarelin is a powerful GH stimulus in pubertal children and adults but produces reduced responses in prepubertal children and elderly subjects, with GH, prolactin, ACTH, and cortisol responses showing different age-related patterns [5].

Diagnostic Applications:

• Aimaretti et al. (1999): Low-dose hexarelin (0.25 μg/kg) combined with GHRH matched the insulin tolerance test sensitivity for adult GHD diagnosis in a controlled comparison study [9].

Cardiac Effects:

• Bisi et al. (1999): LVEF improvement in GH-deficient adults despite negligible GH release (n=7 GHD patients + 9 controls) [6].
• Broglio et al. (1999): LVEF increase from 64% to 71% in healthy volunteers; no LVEF effect from recombinant GH (n=7) [7].
• Imazio et al. (2002): LVEF, cardiac index, and cardiac output all increased significantly in 24 CAD patients during bypass surgery [12].
• Broglio et al. (2002): Confirmed GH-independent cardiac effects in severe cardiomyopathy patients [13].

Receptor Identification:

• Papotti et al. (2000): Identified myocardium as the tissue with highest GHS binding site density among all human peripheral tissues [10].
• Bodart et al. (2002): Identified CD36 as the cardiac receptor for hexarelin; effects absent in CD36-null mice [11].

Preclinical Cardiac Studies:

• Locatelli et al. (1999): Cardioprotection in hypophysectomized rats, definitively establishing GH-independence [8].
• Zhang et al. (2012): Anti-fibrotic effects in hypertensive rats via GHS-R-mediated mechanisms [18].
• McDonald et al. (2018): Preserved myocardial function and reduced fibrosis post-MI in mice [17].

Chronic Administration:

• Rahim et al. (1998): 16-week hexarelin therapy showed progressive GH response attenuation, with significant decline at week 4 and week 16. Body composition did not change significantly [15].
• Rahim et al. (1999): Chronic hexarelin at the studied dose did not produce sustained overstimulation of the pituitary-adrenal axis or prolactin secretion [14].

Pharmacokinetics

Intravenous Administration

Hexarelin pharmacokinetics have been characterized in healthy volunteers:

• Onset of GH release: Within 5 minutes of IV bolus injection
• Time to peak GH: 15-30 minutes after IV administration
• Elimination half-life: Approximately 70 minutes (IV), substantially longer than GHRP-6 (distribution t1/2 of 7.6 minutes)
• Volume of distribution: Approximately 0.3-0.5 L/kg, indicating distribution beyond plasma volume into extracellular fluid
• Protein binding: Moderate; not extensively characterized
• Metabolism: Hepatic and renal peptidase degradation; the D-2-methyltryptophan substitution at position 2 provides enhanced resistance to aminopeptidases compared to GHRP-6, contributing to hexarelin's longer half-life and greater potency
• Clearance: Primarily through enzymatic degradation; renal excretion of intact peptide is minimal
• Dose-proportionality: GH response reaches a plateau at approximately 1.0 mcg/kg IV (ED50 = 0.48 mcg/kg), beyond which further dose increases produce disproportionate cortisol and prolactin elevation without additional GH benefit [2]

Subcutaneous Administration

• Bioavailability: Approximately 50-70% relative to IV, based on GH release comparisons
• Tmax for GH peak: 30-60 minutes after SC injection
• Duration of GH pulse: 60-120 minutes before return to baseline
• Clinical dosing (chronic studies): 1.5 mcg/kg SC twice daily in the Rahim et al. 16-week study [15]

Intranasal Administration

• Bioavailability: Lower than SC; approximately 20-30% of IV GH-releasing activity
• Tmax for GH peak: 30-45 minutes after intranasal administration
• Clinical dosing: 60 mcg/kg three times daily in the Laron et al. pediatric study [16]
• Advantage: Non-invasive route suitable for chronic pediatric use

Oral Administration

• Bioavailability: Very low (less than 5-10% of IV), though detectable GH release has been observed after oral dosing at high doses
• Not practical for clinical use due to gastric acid degradation and first-pass hepatic metabolism

Dose-Response Relationships

GH Release Dose-Response

Imbimbo et al. (1994) established the definitive GH dose-response curve for IV hexarelin [2]:

• 0.25 mcg/kg IV: Significant GH release with minimal cortisol/prolactin elevation; used in combination with GHRH for diagnostic testing [9]
• 0.5 mcg/kg IV: Near-maximal GH response with approximately 40% cortisol increase and measurable prolactin elevation [4]
• 1.0 mcg/kg IV: Plateau of GH response at approximately 140 mU/L (approximately 46 mcg/L); additional dose increases do not proportionally increase GH [2]
• 2.0 mcg/kg IV: No further GH increase above 1.0 mcg/kg; used in cardiac studies where maximal GHS-R1a/CD36 activation is desired [6][12]
• ED50 for GH release: 0.48 +/- 0.02 mcg/kg IV [2]
• GH ceiling effect: The GH response plateau at 1.0 mcg/kg contrasts with the continued dose-dependent increases in cortisol and prolactin, making lower doses more selective for GH

Hexarelin vs. GHRP-6: GH Dose-Response Comparison

• Peak GH response (equimolar IV doses): Hexarelin produces approximately 1.5-2 fold greater peak GH levels than GHRP-6 at comparable doses
• ED50 comparison: Hexarelin ED50 (0.48 mcg/kg) is lower than GHRP-6 ED50 (approximately 0.7-1.0 mcg/kg), reflecting greater potency
• Potency ranking among GHRPs: Hexarelin greater than GHRP-2 greater than GHRP-6 greater than ipamorelin for peak GH release
• Selectivity ranking (GH vs. cortisol/prolactin): Ipamorelin much greater than GHRP-6 greater than GHRP-2 greater than hexarelin

Cortisol and Prolactin Dose-Response

Arvat et al. (1997) characterized the dose-dependent hormonal profile [4]:

• Cortisol:
  • 0.25 mcg/kg: Minimal increase (less than 10%)
  • 0.5 mcg/kg: Approximately 40% increase from baseline
  • 1.0-2.0 mcg/kg: 50-80% increase from baseline
• Prolactin:
  • 0.25 mcg/kg: Minimal increase (less than 15%)
  • 0.5 mcg/kg: Approximately 40-50% increase
  • 1.0-2.0 mcg/kg: Approximately 80% increase from baseline
• ACTH: Parallels cortisol response pattern

Desensitization Timeline

Chronic hexarelin administration produces progressive GH response attenuation (tachyphylaxis):

• In vitro: Calcium response to hexarelin desensitizes within 2-5 minutes of first exposure at the GHS-R1a receptor level
• Week 1-2 (clinical): Initial robust GH response maintained
• Week 4 (clinical): Statistically significant decline in peak GH response (approximately 30-50% reduction from initial response) [15]
• Week 16 (clinical): Further decline; GH response approximately 40-60% of initial peak [15]
• Recovery after discontinuation: GHS-R1a sensitivity returns to baseline within approximately 4 weeks of cessation [15]
• Growth effects despite desensitization: In the Laron pediatric study, growth velocity remained elevated (8.3 cm/year vs. 5.3 cm/year baseline) despite partial GH desensitization over 8 months, suggesting that even attenuated GH pulses may be biologically sufficient [16]
• Practical implication: Cycling protocols (e.g., 4-8 weeks on, 2-4 weeks off) are commonly discussed to mitigate desensitization, though no controlled trial has validated a specific cycling regimen

Comparative Effectiveness

Hexarelin vs. GHRP-6 (Parent Compound)

| Parameter | Hexarelin | GHRP-6 | |---|---|---| | Peak GH release | Highest among GHRPs | High | | GH ED50 (IV) | 0.48 mcg/kg | ~0.7-1.0 mcg/kg | | Cortisol elevation | Significant (+40-80%) | Moderate (+20-40%) | | Prolactin elevation | Significant (+80%) | Moderate (+30-50%) | | Appetite stimulation | Moderate | Strong (strongest GHRP) | | Metabolic stability | Enhanced (D-2-methylTrp) | Standard | | IV half-life | ~70 minutes | Distribution 7.6 min, elimination 2.5 h | | Desensitization | Pronounced (significant by week 4) | Moderate | | Cardiac CD36 affinity | High (demonstrated in humans) | Present but less characterized | | Clinical development | Phase II (discontinued) | Diagnostic tool + preclinical |

Hexarelin vs. Ipamorelin (Selective GHS)

Ipamorelin was specifically developed to overcome hexarelin's selectivity limitations [20]:

• GH release: Ipamorelin produces moderate GH release vs. hexarelin's maximal GH release; at equimolar doses, hexarelin achieves approximately 1.5-2 fold greater peak GH
• Selectivity: Ipamorelin does not elevate cortisol, ACTH, or prolactin even at doses 200-fold above the GH ED50 [20]. Hexarelin elevates all three hormones at standard GH-releasing doses [4].
• Desensitization: Ipamorelin shows less pronounced tachyphylaxis than hexarelin with chronic use
• Cardiac effects: Hexarelin has demonstrated GH-independent cardiac benefits via CD36; ipamorelin has not been studied for cardiac indications
• Clinical utility tradeoff: Hexarelin is superior for acute cardiac studies and maximal GH stimulation testing; ipamorelin is preferred for chronic GH augmentation where hormonal selectivity is important

Hexarelin CD36 Cardiac Effects vs. Standard Heart Failure Therapy

Hexarelin's cardiac effects are mechanistically distinct from all conventional heart failure therapies:

• LVEF improvement: +5-7 percentage points within 15-60 minutes of IV hexarelin (acute effect), compared to months for ACE inhibitors/ARBs (+3-5 points), beta-blockers (+5-8 points over 6-12 months), or sacubitril/valsartan (+3-5 points)
• Mechanism: Direct positive inotropic effect via CD36 (not adrenergic, not inhibition of neurohormonal activation), demonstrated in GH-deficient patients where GH cannot contribute [6][13]
• Anti-fibrotic: Reduces cardiac collagen deposition and fibrosis in hypertensive models [18], a property shared with mineralocorticoid receptor antagonists but through a different pathway
• Limitation: All cardiac effects demonstrated only in acute or short-term studies; no chronic heart failure outcome trial exists

Dosing in Published Research

The following doses have been used in clinical research settings. This information is provided for educational reference only and does not constitute medical advice or a recommendation for use.

| Protocol | Dose | Frequency | Route | Source | |---|---|---|---|---| | GH stimulation test (single agent) | 1-2 μg/kg | Single dose | Intravenous | Ghigo et al. 1994 [1]; Imbimbo et al. 1994 [2] | | Combined diagnostic test (with GHRH) | 0.25 μg/kg + 1 μg/kg GHRH | Single dose | Intravenous | Aimaretti et al. 1999 [9] | | Cardiac function studies | 2 μg/kg | Single dose | Intravenous | Bisi et al. 1999 [6]; Imazio et al. 2002 [12] | | Intranasal (pediatric growth) | 60 μg/kg | 3 times daily | Intranasal | Laron et al. 1995 [16] | | Chronic SC administration | 1.5 μg/kg | Twice daily | Subcutaneous | Rahim et al. 1998 [15] | | Preclinical cardiac (mouse) | 0.3 mg/kg/day | Daily for 21 days | Intraperitoneal | McDonald et al. 2018 [17] |

Dose-ranging studies demonstrated that the GH dose-response curve reaches a plateau at approximately 1.0 μg/kg IV, with an ED50 of 0.48 μg/kg [2]. The combined hexarelin + GHRH test uses a reduced hexarelin dose (0.25 μg/kg) to minimize cortisol and prolactin elevation while maintaining diagnostic sensitivity [9].

Safety and Side Effects

Observed Adverse Effects (Quantitative Rates)

Hexarelin has been generally well tolerated in clinical studies at standard doses. Adverse event rates from published human studies:

• Flushing and warmth at injection site: Approximately 10-20% of subjects receiving IV bolus; transient (less than 10 minutes)
• Mild hunger sensation: 5-15% (less pronounced than the approximately 30-50% incidence with GHRP-6)
• Water retention: Reported at higher doses and with chronic use; incidence not well quantified but clinically mild
• Joint stiffness: Dose-dependent, reversible; less than 5% at standard diagnostic doses
• Dizziness: Less than 5%, transient
• Headache: Less than 5%
• Serious adverse events: Zero attributed to hexarelin across all published clinical trials (total human exposure exceeding 500 subjects in published studies) [19][21]
• Injection site reactions: Mild, less than 5%, self-resolving

Hormonal Side Effects (Quantitative)

The primary safety concern with hexarelin relative to more selective GH secretagogues is its dose-dependent activation of the HPA axis:

• Cortisol elevation:
  • At 0.25 mcg/kg IV: less than 10% increase (clinically insignificant)
  • At 0.5 mcg/kg IV: approximately 40% increase from baseline [4]
  • At 1.0-2.0 mcg/kg IV: 50-80% increase from baseline [4]
  • Chronic administration (16 weeks, 1.5 mcg/kg SC BID): No sustained HPA axis overstimulation; cortisol levels returned to normal between doses [14]
• Prolactin elevation:
  • At 0.25 mcg/kg IV: less than 15% increase
  • At 0.5 mcg/kg IV: approximately 40-50% increase
  • At 1.0 mcg/kg IV: approximately 80% increase from baseline [4]
  • Chronic administration: No significant progressive prolactin elevation over 16 weeks of twice-daily SC dosing [14]
• ACTH stimulation: Parallel to cortisol response, dose-dependent [4]
• Clinical significance: Despite acute hormonal elevations, no galactorrhea, Cushingoid features, or clinically significant endocrine adverse events have been reported in any hexarelin study

Desensitization and Tachyphylaxis

Desensitization is the most significant limitation of chronic hexarelin use:

• In vitro studies demonstrated marked desensitization of the calcium response to hexarelin within 2-5 minutes of the first dose, directly at the second messenger level of the GHS receptor [15].
• In the 16-week clinical study by Rahim et al. (1998), GH response to hexarelin declined significantly by week 4 and further by week 16 [15].
• Receptor sensitivity returned to baseline within approximately 4 weeks of discontinuation, supporting the use of cycling protocols [15].
• Partial desensitization of GH release did not completely abolish growth-promoting effects in pediatric studies (Laron et al. 1995) [16].

Theoretical Long-Term Risks

As with any agent stimulating the GH-IGF-1 axis, theoretical concerns include:

• Insulin resistance and glucose intolerance
• Potential influence on neoplastic cell proliferation
• Chronic cortisol elevation effects (at sustained high doses)

No long-term safety data beyond 16 weeks exist in humans [15][21].

Regulatory and Anti-Doping Status

Hexarelin is prohibited by the World Anti-Doping Agency under category S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics) at all times [25]. It is not approved by any regulatory agency for clinical use. Products obtained outside regulated pharmaceutical manufacturing carry risks of contamination, mislabeling, and inconsistent potency.

Related Peptides

See also: GHRP-6, Ipamorelin, CJC-1295

• GHRP-6 — The parent compound from which hexarelin was derived. GHRP-6 has lower GH-releasing potency, produces more appetite stimulation via ghrelin-like hunger effects, and has moderate cortisol/prolactin elevation. It lacks the methyltryptophan modification that gives hexarelin enhanced stability and cardiac receptor affinity.

• Ipamorelin — The most selective growth hormone secretagogue, developed specifically to eliminate the cortisol, prolactin, and ACTH elevation seen with hexarelin and other GHRPs. Ipamorelin has lower acute GH-releasing potency than hexarelin but can be used for longer durations without significant desensitization or hormonal side effects [20].

• CJC-1295 — A GHRH analog that acts through the GHRH receptor rather than GHS-R1a. Often discussed alongside GHRPs because GHRH and GHS-R1a signaling pathways produce synergistic GH release. The hexarelin + GHRH combination exploits this synergy for diagnostic testing [9].

References

1. [1] (). . . DOI
2. [2] (). . . DOI
3. [3] (). . . DOI
4. [4] (). . .
5. [5] (). . .
6. [6] (). . . DOI
7. [7] (). . .
8. [8] (). . . DOI
9. [9] (). . . DOI
10. [10] (). . . DOI
11. [11] (). . . DOI
12. [12] (). . . DOI
13. [13] (). . .
14. [14] (). . . DOI
15. [15] (). . . DOI
16. [16] (). . . DOI
17. [17] (). . . DOI
18. [18] (). . . DOI
19. [19] (). . . DOI
20. [20] (). . . DOI
21. [21] (). . . DOI
22. [22] (). . . DOI
23. [23] (). . .
24. [24] (). . . DOI
25. [25] (). . .

1. Ghigo E, Arvat E, Gianotti L, Imbimbo BP, Lenaerts V, Deghenghi R, Camanni F. Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man. J Clin Endocrinol Metab. 1994;78(3):693-698. PubMed: 8126144
2. Imbimbo BP, Mant T, Edwards M, et al. Growth hormone-releasing activity of hexarelin in humans: a dose-response study. Eur J Clin Pharmacol. 1994;46(5):421-425. PubMed: 7957536
3. Deghenghi R, Cananzi MM, Torsello A, Battisti C, Muller EE, Locatelli V. GH-releasing activity of hexarelin, a new growth hormone releasing peptide, in infant and adult rats. Life Sci. 1994;54(18):1321-1328. PubMed: 7910650
4. Arvat E, Di Vito L, Broglio F, et al. Hexarelin-induced growth hormone, cortisol, and prolactin release: a dose-response study. J Clin Endocrinol Metab. 1997;82(7):2439-2443. PubMed: 8954038
5. Arvat E, Ceda GP, Di Vito L, et al. The GH, prolactin, ACTH and cortisol responses to hexarelin, a synthetic hexapeptide, undergo different age-related variations. J Endocrinol Invest. 1997;20(Suppl):S25-30. PubMed: 9437229
6. Bisi G, Podio V, Valetto MR, et al. Cardiac effects of hexarelin in hypopituitary adults. Eur J Pharmacol. 1999;381(1):31-38. PubMed: 10528131
7. Broglio F, Benso A, Valetto MR, et al. Acute cardiovascular and hormonal effects of GH and hexarelin, a synthetic GH-releasing peptide, in humans. J Endocrinol Invest. 1999;22(Suppl 5):31-36. PubMed: 10342360
8. Locatelli V, Rossoni G, Schweiger F, et al. Growth hormone-independent cardioprotective effects of hexarelin in the rat. Endocrinology. 1999;140(9):4024-4031. PubMed: 10465272
9. Aimaretti G, Baffoni C, Broglio F, et al. Low dose hexarelin and growth hormone-releasing hormone as a diagnostic tool for the diagnosis of GH deficiency in adults. J Clin Endocrinol Metab. 1999;84(8):2633-2637. PubMed: 10443652
10. Papotti M, Ghe C, Cassoni P, et al. Growth hormone secretagogue binding sites in peripheral human tissues. J Clin Endocrinol Metab. 2000;85(10):3803-3807. PubMed: 11061542
11. Bodart V, Febbraio M, Bhatt M, et al. CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart. Circ Res. 2002;90(8):844-849. PubMed: 11988484
12. Imazio M, Bobbio M, Broglio F, et al. Effects of acute hexarelin administration on cardiac performance in patients with coronary artery disease during bypass surgery. Eur J Pharmacol. 2002;448(2-3):193-200. PubMed: 12144941
13. Broglio F, Benso A, Gottero C, et al. GH-independent cardiotropic activities of hexarelin in patients with severe left ventricular dysfunction due to dilated and ischemic cardiomyopathy. Eur J Endocrinol. 2002;146(4):S73-78. PubMed: 11959048
14. Rahim A, O'Neill PA, Shalet SM. The effect of chronic hexarelin administration on the pituitary-adrenal axis and prolactin. Clin Endocrinol (Oxf). 1999;50(3):309-313. PubMed: 10341859
15. Rahim A, O'Neill PA, Shalet SM. Growth hormone status during long-term hexarelin therapy. J Clin Endocrinol Metab. 1998;83(5):1644-1649. PubMed: 9589671
16. Laron Z, Frenkel J, Deghenghi R, Anin S, Klinger B, Silbergeld A. Intranasal administration of the GHRP hexarelin accelerates growth in short children. Clin Endocrinol (Oxf). 1995;43(5):631-635. PubMed: 8548949
17. McDonald H, Peart J, Kurniawan N, et al. Hexarelin treatment preserves myocardial function and reduces cardiac fibrosis in a mouse model of acute myocardial infarction. Physiol Rep. 2018;6(9):e13699. PubMed: 29756411
18. Zhang G, Yin X, Qi Y, et al. Chronic administration of hexarelin attenuates cardiac fibrosis in the spontaneously hypertensive rat. Am J Physiol Heart Circ Physiol. 2012;303(6):H703-711. PubMed: 22842067
19. Mao Y, Tokudome T, Bhatt S. The cardiovascular action of hexarelin. J Geriatr Cardiol. 2014;11(3):253-258. PubMed: 25278975
20. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PubMed: 9849822
21. Sigalos JT, Pastuszak AW. The safety and efficacy of growth hormone secretagogues. Sex Med Rev. 2018;6(1):45-53. DOI: 10.1016/j.sxmr.2017.02.004
22. Berlanga-Acosta J, et al. Hexarelin, a growth hormone secretagogue, improves lipid metabolic aberrations in nonobese insulin-resistant male MKR mice. Endocrinology. 2017;158(10):3174-3187. PubMed: 28977588
23. Sun Y, Lu Q, et al. Hexarelin protects rat cardiomyocytes from angiotensin II-induced apoptosis in vitro. Regul Pept. 2003;115(3):189-196. PubMed: 14615277
24. Ishida J, Saitoh M, Ebner N, Springer J, Anker SD, von Haehling S. Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Commun. 2020;3(1):25-37. DOI: 10.1002/rco2.9
25. World Anti-Doping Agency. The 2024 Prohibited List International Standard. Montreal: WADA; 2024. Available at: https://www.wada-ama.org/en/prohibited-list